Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22288637 | 1.00 | TDP1 (0.32) | TDP1L3MBTL1ADORA2AADORA1MEN1 | |
| SCHEMBL660639 | 0.83 | KDM1A (0.32) | TDP1L3MBTL1ADORA2AADORA1MEN1 | |
| SCHEMBL16680822 | 0.78 | TRPV4 (0.37) | TDP1L3MBTL1TRPV4 | |
| SCHEMBL22977517 | 0.78 | L3MBTL1 (0.33) | TDP1L3MBTL1ADORA2AADORA1MEN1 | |
| SCHEMBL30301279 | 0.78 | TRPV4 (0.37) | TDP1L3MBTL1TRPV4 | |
| SCHEMBL2597730 | 0.78 | TRPV4 (0.37) | ADORA2AADORA1ALDH1A1HSD17B10TRPV4 | |
| SCHEMBL29906554 | 0.78 | TRPV4 (0.37) | ADORA2AADORA1ALDH1A1HSD17B10TRPV4 | |
| SCHEMBL16122475 | 0.77 | TRPV4 (0.36) | TDP1L3MBTL1TRPV4 | |
| SCHEMBL23847038 | 0.75 | TDP1 (0.42) | TDP1L3MBTL1ADORA2AADORA1MEN1 | |
| SCHEMBL15264472 | 0.75 | GRM6 (0.36) | TDP1L3MBTL1ADORA2AADORA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240825-B2 | Oxexin 1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-03-04 | — | — | US | disclosed |
| US-20220098165-A1 | OXEXIN 1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098165-A1 | OXEXIN 1 RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, OXTR | TDP1 3239/4885L3MBTL1 2222/4885ADORA2A 407/4885 |
| US-12240825-B2 | Oxexin 1 receptor antagonists | HCRTR1, HCRTR2, OXTR | TDP1 3239/4885L3MBTL1 2222/4885ADORA2A 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.